RDY

Dr. Reddy's Laboratories Ltd

68.08 USD

Last updated Nov 28, 19:08 UTC

Yesterday HIGH

$68.23

Yesterday LOW

$67.54

52w HIGH

$73.17

52w LOW

$51.11

EPS

1.07

PE

63.63

Next Earnings

Jan 24, 2024

Overview News Government Trades

Dr. Reddy's Laboratories Ltd stock is up 5.11% since 30 days ago. The next earnings date is Jan 24, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 69.57% of the previous 22 November’s closed higher than October.

Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients, Proprietary Products, and Others segments. Its therapeutic categories include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology.

Stock Exchange

NYSE

Sector

Manufacturing

Industry

Pharmaceutical Products

Headquarters

Hyderabad, India

Website

Vandana Singh

Mon Feb 27, 2023

Dr. Reddy's Seeks Gaining Foothold In Women's Health Via Mayne Pharma's U.S. Generic Prescription Deal
Charles Gross

Mon Feb 27, 2023

Dr. Reddy's Laboratories Announced Late Sunday Agreement To Acquire Mayne Pharma's U.S. Generic Prescription Product Portfolio

Dr. Reddy's Laboratories SA, wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd. (NYSE: RDY) announced that it has entered into a definitive agreement to acquire the U.S. generic prescription product portfolio of Salisbury, Australia, based Mayne Pharma Group Limited (ASX: MYX).
Charles Gross

Fri Jan 13, 2023

Dr Reddy's Laboratories Ltd Launches In-house Palbociclib To Widen Access To High-quality Breast Cancer Drug For Indian Market
Vandana Singh

Tue Dec 20, 2022

Journey Medical Touts Positive PK Data For Bacterial Infection Candidate
Benzinga Newsdesk

Mon Dec 19, 2022

Dr. Reddy's Completes Phase 1 Study Of DRL_TC, A Proposed Biosimilar Of Tocilizumab

Tocilizumab is an important anti-rheumatic agent used in the treatment of adult patients with moderate to severe active rheumatoid arthritis who have had an inadequate response to one or more Disease-Modifying
Benzinga Newsdesk

Mon Oct 31, 2022

Barclays Maintains Overweight on Dr Reddy's Laboratories, Raises Price Target to $67

Barclays analyst Balaji Prasad maintains Dr Reddy's Laboratories (NYSE:RDY) with a Overweight and raises the price target from $66 to $67.
Benzinga Newsdesk

Tue Oct 25, 2022

Barclays Maintains Overweight on Dr Reddy's Laboratories, Lowers Price Target to $66

Barclays analyst Balaji Prasad maintains Dr Reddy's Laboratories (NYSE:RDY) with a Overweight and lowers the price target from $69 to $66.
Vandana Singh

Fri Oct 14, 2022

Novartis Fails To Prevent Generic Competition For Its Blockbuster Multiple Sclerosis Drug

The U.S. Supreme Court rejected Novartis AG's (NYSE: NVS) effort to block the launch of generic versions of its multiple sclerosis drug Gilenya.
Benzinga Newsdesk

Mon Sep 12, 2022

Barclays Maintains Overweight on Dr Reddy's Laboratories, Raises Price Target to $69

Barclays analyst Balaji Prasad maintains Dr Reddy's Laboratories (NYSE:RDY) with a Overweight and raises the price target from $68 to $69.
Bill Haddad

Wed Sep 7, 2022

Dr. Reddy's Laboratories Announces Launch Of Lenalidomide Capsules In US With Two Of Six Strengths Eligible For First-to-market, 180-Day Exclusivity

AMZN $146.89 USD

WDAY $237.48 USD

CRWD $212.48 USD

DLTR $116.18 USD

FLNC $20.14 USD

BILI $13.28 USD

UVXY $10.18 USD